Prof. Papadopoulos is Professor of Allergy and Paediatric Allergy at the University of Manchester, UK, and the Chair of Allergy and Pediatric Allergy at the University of Athens (NKUA), Greece.
He has extensive clinical and educational experience in paediatric allergy, having headed for many years a unit caring for more than 7,000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians and allergists. His research focus is the interface between infection and allergic disease, with an emphasis on asthma exacerbations and food allergy. He is the Coordinator of the EU-funded CURE project. He has extensive collaborations in the context of EU projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST.
Prof. Papadopoulos has published over 300 papers (h-index: 70), has received several international awards and is invited to speak at international scientific meetings some 30 times a year. Moreover, he has served or is serving on the boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013–2015 President of EAACI and is currently the President of the Respiratory Effectiveness Group (REG).

Antonio Anzueto is Professor of Medicine at the University of Texas Health Science Center and Chief of the Pulmonary Section for the South Texas Veterans Health Care System, San Antonio, Texas, USA. In addition, he is a faculty member of the Pulmonary Disease and Critical Care Medicine Division, the Medical Director for the Pulmonary Function Laboratory at the University Hospital in San Antonio, and an adjunct scientist at the Southwest Foundation for Biomedical Research, San Antonio, Texas.
His areas of interest include chronic obstructive pulmonary disease, chronic bronchitis, community-acquired pneumonia, sepsis, acute respiratory distress syndrome, and lung transplantation.
He is a member of a number of medical committees, a reviewer for various scientific journals including the New England Journal of Medicine, and has published over 250 manuscripts in highly rated medical journals. He has extensive research experience as has been the principal investigator of numerous large multicenter clinical trials. He is member of several international committees such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD); ATS/IDSA Community Acquired Pneumonia Guidelines Committee; International committee – consensus conference on ALI/ARDS. He is also a practicing physician that has been nominated over the last 8 years as a “Best Pulmonary Doctor” in San Antonio, Texas.

Sinthia Bosnic-Anticevich is Professor at the Woolcock Institute of Medical Research, University of Sydney. Internationally recognized as a leader in in the field of respiratory medicines, she is the founder and Team Leader of the Quality Use of Respiratory Medicines Group, located at the Woolcock Institute, University of Sydney and Sydney Local Health District. The group focuses on generating new knowledge about the use of respiratory medicines from the patient, health care provider and societal perspective with output of over 120 research publications. The research of Sinthia and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines.
Sinthia is on the executive of ARIA (Allergic Rhinitis in Asthma) and chair of Pharmacy ARIA, which is the leading global initiative for the management of Allergic Rhinitis in pharmacy. She is Vice President of the Respiratory Effectiveness Group (REG). Sinthia sits on several global advisory boards associated with the use of medicines in the management of respiratory diseases. Sinthia is actively involved in the practice of pharmacy and committed to the education of current and future health care providers around the use of respiratory medicines in practice.

Giorgio Walter Canonica is Professor of Respiratory Medicine at Humanitas University & Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital - Milano, Italy. Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.

Dr. Christopher Carlsten is director of the Centre for Lung Health, a professor and head of the Respiratory Medicine Division at the University of British Columbia (UBC). He is a Canada Research Chair in Occupational and Environmental Lung Disease and holds the Astra-Zeneca Chair in Occupational and Environmental Lung Disease at UBC. He is the director of both the Legacy for Airway Health and the Air Pollution Exposure Laboratory, and also holds adjunct positions at the Peter Wall Institute for Advanced Studies and the UBC School of Population and Public Health. He attended undergraduate and medical school at Stanford University before training in internal, occupational, pulmonary and critical care medicine at the University of Washington.
Dr. Carlsten’s clinical and research interests center on occupational airways disease, including the effects of diesel exhaust and other inhaled exposures on asthma induction and exacerbation. His laboratory investigates the cardio-pulmonary-immunological health effects of inhaled environmental and occupational exposures, using diesel exhaust, western red cedar and phthalates as model inhalants. Across these domains, he focuses on community-partnered engagement, reducing disparities, and narrowing the gaps between the academic and applied realms of health care, prevention and related policy. As director of the Occupational Lung Disease Clinic at Vancouver General Hospital’s Lung Centre, he welcomes patients with concerns regarding occupational or environmental exposures contributing to respiratory disease including asthma, COPD, interstitial lung disease, cancer and pleural disease.

Sebastian L Johnston: is Professor of Respiratory Medicine & Allergy and Head of the Airway Diseases Section at the National Heart and Lung Institute, Imperial College London. He is the Asthma UK Clinical Professor and is a UK National Institute of Health Research Senior Investigator. He Edited Thorax from 2002-2010 and serves as Associate Editor or on the Editorial Boards of several other Respiratory and Allergy Journals. He has published >450 scholarly manuscripts and 18 patents. Notable achievements include establishing the viral aetiology of the majority of asthma and COPD exacerbations, discovering novel mechanisms of susceptibility to virus infection in asthma and COPD, and developing novel treatment approaches for acute exacerbations of these diseases.

Chairperson of the Family Physician Airways Group of Canada (www.fpagc.com)
Past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada
Senate member of the International Primary Care Respiratory Group
President of the IPCRG 5th biennual world scientific meeting, “Making Every Breath Count” Toronto June 2-5, 2010
Chair of the Council of Organizing Members of the Canadian Network for Respiratory Care.
Member of Past Canadian Consensus Guidelines for H pylori, Asthma, COPD and Sinusitis
Representative of the College of Family Physicians of Canada to the SARS clinical working group.
Member of Chronic Respiratory Disease Surveillance Advisory Committee (Public Health Agency of Canada)
Member of the Health Canada Section on Allergy and Respiratory Therapies
Member of the Canadian Metropolitan Tuberculosis Subcommittee
Co-Chair, Health Quality Ontario COPD Community Management standards committee
Board member, Thrombosis Canada
Vice President, Respiratory Effectiveness Group

International editor for Nature’s Primary Care Respiratory Journal
International editor for the Italian Journal of Primary Care

Non-respiratory medical interests:
Community Pain consultant
Palliative Care community physician
Hospitalist, Brampton Civic Hospital

Social:
Married with four children and four dogs
Ardent baseball player

Dr Konstantinos Kostikas is Associate Professor of Respiratory Medicine and Head of the Respiratory Medicine Department of the University of Ioannina, Greece, and Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute, Singapore. He was trained at the University of Athens Medical School and the Royal Brompton Hospital, London, and has worked in academia and the pharmaceutical industry in global medical affairs roles.
Dr Kostikas is a member of GOLD COPD Assembly. He has more than 230 publications in PubMed (h-index 38), focusing on COPD, severe asthma, and new technologies. He is the Editor in Chief of Pneumon Journal (www.pneumon.org), associate editor of COPD: Journal of Chronic Obstructive Pulmonary Disease, and member of the editorial board of American Journal of Respiratory and Critical Care Medicine, PLoS One, Diagnostics and Frontiers in Medicine.

- MD, FAAAAI, Dist.Intl.FACAAI
- Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Mexico City
- GINA Advocate for Mexico 2020-ongoing
- Chair 8 National Guidelines: a.o. Integrated asthma managemente (MIA 2021), Immunotherapy 2019, Consensus Atopic Derm 2018, Asthma 2017, Urticaria 2014 and ARIA México 2014
>190 pubmed indexed publications

Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).

Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes, France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is a member of the GOLD science committee, President of Société de Pneumologie de Langue Française, co-chair of the 2018 ERS Congress and member of the American Thoracic Society. He is guidelines director of the ERS and member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council, vice-president of the Respiratory Effectiveness Group and member of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national projects on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.

Dermot Ryan is a recently retired GP who has had a long-term interest in Respiratory and Allergic diseases regarding primary care. He was previously chair of Primary Care Society during which time he was instrumental in establishing the professorial post of Professor in Primary Care Respiratory Medicine, the first ever clinical discipline to be established in any academic department of primary care. During this time, he was involved in the set-up of what is now npj Primary Care Respiratory Medicine. The purpose of these two activities were to research real life solutions to the real-life problems encountered in daily practice and provide a vehicle for the dissemination of this research. He was previously the Clinical Respiratory lead of East Midland Strategic Health Authority. He was the first chair of the primary care interest group of EAACI where he served (and is still serving) on many task forces. He succeeded David Price as president of REG and in turn was succeeded by Nikos Papadopoulos. He is Honorary Clinical Research Fellow at the University of Edinburgh.

Joan B Soriano graduated in Medicine in 1993 and received his Ph.D. in Epidemiology and Methodology of Biomedical Research in 1996, both from the Universitat Autònoma de Barcelona. He completed his education in Epidemiology with a Master of Science at the Erasmus University Rotterdam, The Netherlands, and a post-doctoral stay at the Johns Hopkins School of Public Health, in Baltimore, USA. He worked in the pharmaceutical industry in the UK from 1998, and later in the USA from 2003. In 2005 moved back to CIMERA in Mallorca, Spain, up to its closing. From 2015, he is Associate Professor of Medicine at the Universidad Autónoma de Madrid, Senior Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, both in Madrid.
He serves in the GesEPOC COPD guidelines, has been Methodologic and Scientific Consultant of SEPAR and Director of its Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational Medicine. Since 2007 he is Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine, and peer reviews extensively for others. He has 300+ publications in PubMed in the fields of clinical epidemiology and treatment of respiratory diseases, and a Hirsh index of 80+. In May 2011 he received the Josep Trueta Award for scientific and medical achievements, and in 2014 he was appointed FCCP from Chest and Foundational Fellow of the ERS (FERS).
He has authored several REG papers and participated actively in many of its past conferences. He is in the REG Board since 2019.

Omar Usmani is a Reader and Consultant Physician in Respiratory Medicine at the National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital. He qualified in Medicine at King’s College London and completed his PhD at Imperial College London for which he received the 2005 NHLI Imperial College PhD Prize for the best thesis.
His clinical research themes are Inhaled Drug Delivery, Airways Physiology, Lung Imaging, Respiratory Pharmacology and Tele-monitoring / E-health. He is Secretary of Assembly 5 (Asthma and COPD) at the ERS, Chair of UKIG (UK Inhaler Group), Vice-Chair of Drug Delivery to the Lungs, and Europe Liaison of International Society of Aerosols in Research (ISAM).
In 2012, he was awarded a UK National Institute for Health Research (NIHR) Career Development Fellowship, the first time this award category was given to Respiratory Science research in the UK. In 2015, received one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognizing his international research excellence in pharmaceutical aerosols and inhalable materials.
He is currently clinical lead on an EU Horizon 2020 consortium project ‘myaircoach’ focusing on the tele-monitoring of patients with asthma and is PI of an FDA awarded project on understanding patient perceptions in breathing from a DPI.

Federico Lavorini is Professor of Respiratory Medicine at the Department of Clinical and Experimental Medicine, University of Florence Italy; he is also Head of the Respiratory and Critical Care Unit at the Careggi University Hospital, Florence, Italy. He qualified in Medicine at the University of Florence (1991), has the Specialist Certification in Respiratory Medicine (1996), and he also undertook a Ph.D. board certified in Applied Pathophysiology (2000). His research interests are control of breathing in health and disease, cough and inhalation devices for delivering aerosol medications. At the present, he is member of the Aerosol Drug Management Improvement Team (ADMIT), an european consortium of respiratory physician with special interests in aerosol medicine. He is also member of the Respiratory Effectiveness Group (REG), an investigator-led, social enterprise research initiatve. Federico Lavorini is Co-Chair of the European Respiratory Society /International Society of Aerosol in Medicine Taskforce on inhaled therapy and devices of the. He is also Chair of the Italian Respiratory Society (SIP) Taskforce on aerosol delivery systems. Federico Lavorini is Associate Editor and Review Editor of the Clinical Respiratory Journal, Respiratory Physiology and Pathophysiology, Frontiers in Physiology. He acts as Board member of the International Society for Aerosol in Medicine (ISAM), of the Journal of Aerosol Medicine and Pulmonary Drug Delivery, and of the BioMed Research International, Pulmonology.

Professor Morice is Head of Respiratory Medicine at HYMS, based at the University of Hull. He is also an Honorary Consultant Physician at Hull & East Yorkshire Hospitals NHS Trust. Professor Morice specializes in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specializing in the treatment of asthma and COPD.
The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.
Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.

Prof. Rhee currently serves as the Professor in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine at Seoul St. Mary’s Hospital of The Catholic University of Korea.
Prof. Rhee is an Associate Editor of BMC Pulmonary Medicine. He is a member of editorial board of American Journal of Respiratory and Critical Care Medicine, Journal of COPD, Frontiers in Medicine, Journal of Thoracic Disease, Journal of Korean Medical Science, and Life. He is also a Deputy Editor of Tuberculosis and Respiratory Diseases.
Prof. Rhee is a member of long-range planning committee of ERS Assembly 5, Chairperson of APSR Research Committee, Head of APSR COPD assembly, a member of Planning and Action Committee on APSR Development, APSR Bulletin Coordinator. He is a member of steering committee of International Severe Asthma Registry. He is also a member of many committees of Korean Academy of Tuberculosis and Respiratory Disease.
Prof. Rhee has published 230 SCI(E) articles (95 publications as first/corresponding author). The focus of his research is COPD and asthma.

Dr. Imran Satia is an Assistant Professor in the Department of Medicine, Division of Respirology at McMaster University. His research involves a multi-disciplinary approach to investigate the effects of aging, risk factors, impact, and burden of disease at a population level with respiratory symptoms such as chronic cough. Imran’s main objectives are to understand the neuro-physiological and neuro-immune mechanisms of chronic cough and his long-term vision is to develop novel treatments for patients suffering with such respiratory symptoms to reduce their impact and burden of disease on patient lives. Imran is also a respiratory physician with expertise in the neurophysiology of airway nerves, clinical and experimental research and epidemiological observational cohort studies.

TRAINING
After finishing his medical studies at the University of Basque Country in Bilbao, Ignacio J. Ansotegui moved to the Department of Immunology and Department of Clinical Immunology at the Karolinska Institute and Karolinska Hospital of Stockholm, respectively. He completed his Spanish PhD studies in Sweden, specializing in Immunology. Later, at the University of Rome "La Sapienza", he got his second specialty in Allergology and Clinical Immunology. He is also specialist in Occupational Medicine

CURRENT AND PREVIOUS POSITION
Dr. Ansotegui is Head of Department of Allergy and Immunology at Hospital Quironsalud Bizkaia in Bilbao, Spain.
Actually he serves as Executive Medical Director and Counselor of the World Allergy Organization (WAO), Treasurer of Global Asthma Association (INTERASMA) and Member of the Board of Directors of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI).
After five years in Sweden and six years in Italy, Ignacio J. Ansotegui returned to Spain in 1996 and created the Immunoallergy Laboratory at the Santiago Apostol Hospital in Vitoria-Gasteiz. Later, between 2007 and 2010, he was appointed as Consultant Allergist and Clinical Immunologist at Royal Hospitals as well as Honorary Senior Lecturer at Queen's University of Belfast, UK.
Dr. Ansotegui has chaired the Research Committee of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI). Previously he served as Vice-chair (2009-2010) and Chair (2011-2012) of Iberian Chapter and member of the Board of Directors of SLAAI (2013-2014). Dr Ansotegui was Secretary General of INTERASMA from 2003 to 2006 and he also was Member at Large (2001 to 2003), 2nd Vice President (2003 –2005), Historian (2005 to 2007) and Chair of Ethics Committee (2007-2010) of the European Academy of Allergy and Clinical Immunology (EAACI).  Between 2008 and 2017 he has also been secretary of the European CME Accreditation Committee. In 2008, he was the President of the European Congress of Allergy and Clinical Immunology that was held in Barcelona.
In the World Allergy Organization, Dr. Ansotegui served for four years as member at large of the Board of Directors, two years as Secretary General, two years as President Elect of the Organization and has been President of the Organization 2018-2019.
In 2007, he received the Distinguished Clinical Services Award from the Argentinean Association of Allergy and Clinical Immunology and was honored with the International Distinguished Fellow Award from the American College of Allergy, Asthma and Immunology. In 2014, he has been awarded as Honorary Member of the Italian Society of Allergology, Asthma and Clinical Immunology, and one year later, Honorary Member of the Georgian Association of Allergology and Clinical Immunology. Recently he has also been awarded as Honorary Member of the Lebanese Society of Allergy and Immunology and Honorary Member of the Argentinean Association of Allergology and Clinical Immunology.

MAIN LECTURES AND PUBLICATIONS
Ignacio J. Ansotegui has published over 170 peer reviewed articles in respected journals including Science, Journal Experimental Medicine, Biochemical Journal, Journal of Allergy and Clinical Immunology, Allergy, Journal of Investigational and Clinical Allergy, Clinical Experimental Allergy, Cellular Immunology, Scandinavian Journal of Immunology, Parasitology Today, Hybridoma,  European Journal of Epidemiology, Journal American Academy of Dermatology, International Archives of Allergy and Immunology,  Contact Dermatitis, European Annals of Allergy and Clinical  Immunology, Anticancer Research, WAO Journal, etc.

EDITORIAL ACTIVITY
Dr. Ansotegui has been involved as editorial board member of several journals of the specialty: Allergy, J Investigational Allergy and Clinical Immunology, International Archives of Allergy and Immunology, Annals of Respiratory Medicine, International Trends in Immunity, Asthma Research and Practice, Alergología e Inmunología Clínica and Clinical and Molecular Allergy

Thérèse Lapperre is an Associate Professor in Respiratory Medicine at the University of Antwerp and head of the department of Respiratory Medicine at the Antwerp University Hospital (UZA). She has an international background, being trained in the Netherlands and having worked as a pulmonologist and researcher in both Singapore and Copenhagen, Denmark. Her main research interest involves the pathogenesis and management of patients with COPD and asthma, including clinical and mechanistic studies.

Miriam Barrecheguren is a pneumologist working at Vall d´Hebron University Hospital in Barcelona.
She graduated in Medicine at the University of Santiago de Compostela in 2008. After her training in Respiratory Medicine, she obtained her PhD at the Autonomous University of Barcelona in 2016 on the diagnosis and management of COPD and AATD in Primary Care. Afterwards, she fulfilled a research fellow at McGill University (Montreal, Canada) and obtained a Rio Hortega grant from the Health Institute Carlos III (Madrid, Spain). She was granted the honorary lecture for young researchers of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) in 2018.
She is the European Respiratory Society (ERS) Early Career Member (ECM) representative in the European Alpha-1 research collaboration (EARCO) and has been involved in the development of the international registry of AATD (EARCO)
Her primary interests include COPD, alpha-1 antitrypsin deficiency (AATD) and mechanical ventilation. She has more than 50 peer-reviewed publications indexed in PubMed.

Respiratory Medicine and Intensive Care Consultant
PhD in Public Health (Health Policies, Management and Administration)
Head of Intensive Care Unit of Hospital Pulido Valente - Centro Hospitalar Universitário Lisboa Norte
Advisor to the Portuguese Directorate-General for Health / Department of Health
Member of the Portuguese National Council for Public Health

Arnaud Bourdin is Head of Pulmonology and a Consultant and Professor of Respiratory Medicine at Hôpital Arnaud de Villeneuve, Montpellier, France. He gained his MD and PhD in 2001 and 2006, respectively, from the University of Montpellier, and was subsequently a fellow at Monash University, Melbourne, Australia, working alongside Professor Tom Kotsimbos.
Professor Bourdin is head of a clinical research group investigating innovative treatments for asthma, chronic obstructive pulmonary disease (COPD), rare diseases including idiopathic pulmonary fibrosis and pulmonary hypertension. His scientific research interests include iPSC biology, COPD pathophysiology and management and the mechanisms and treatment of severe asthma.
He has acted as Principal Investigator for a number of trials in asthma and COPD, including the COBRA study and the RAMSES registry. Professor Bourdin is a GINA Advocate since 2020.
He is the French leader for the SHARP European program and board member of the ISAR international initiative for severe asthma, an Organising Committee Member of G2A – Journées d’échange sur l’asthme sévère, and a member of the editorial team and reviewer for three international journals. He is also a member of the European Respiratory Society (ERS), for which he has acted as Chair and speaker for the past 7 years. He was named as a Fellow of the ERS in 2020. He has authored or co-authored more than 250 peer-reviewed articles, reviews and monographs.

Carlos Robalo Cordeiro is the Head of Pulmonology Department at the Coimbra University Hospital and Dean of Coimbra Medical School where he is Full Professor of Pulmonology.
He was President of the Portuguese Society of Pulmonology (2010/2015), Executive Committee member of WASOG – World Association of Sarcoidosis and Other Granulomatosis (2011/2015) and Secretary General of the ERS - European Respiratory Society (2016/2019). He is currently the ERS President (2022/2023).
His main field of interest is Interstitial Lung Disease and Obstructive Airways Diseases, having published around 140 papers in impact factor journals and being peer reviewer of 16 national and international journals and Board member of 8 national and international journals.

Dr. Stefan Cristian Stanel is a member of the REG ILD/IPF working group and part of the steering committee for the REG Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era study.
He is working as an ILD specialist in Manchester, UK. Within the team in Manchester, he is developing one of the first familial interstitial pneumonia (FIP) clinics in the UK, to provide genetic testing and personalized care for patients affected by familial forms of ILD.
In addition, he is currently pursuing doctoral studies with the University of Manchester, researching post COVID-19 pulmonary fibrosis and the impact of circadian disruption on the clinical progression of idiopathic pulmonary fibrosis (IPF). Prior to working in the UK, he trained in Respiratory Medicine in Romania and France, and also undertook a one-year internship at the European Medicines Agency (EMA).
Stefan is committed to improving communication between patients and healthcare providers in alternative ways and is actively developing educational medical content online through his YouTube channels and several websites, in both Romanian and English.

Prof. J. Christian Virchow is head of the departments of pneumology and intensive care medicine at the university medical center in Rostock Germany.
He has published more than 260 peer reviewed papers on pulmonary diseases with a focus on asthma and COPD.

Interstitial Lung Disease Unit, Respiratory Medicine Department
Wythenshawe Hospital
Manchester University NHS Foundation Trust
United Kingdom

Dr Rivera Ortega is a Respiratory Consultant with expertise in interstitial lung diseases (ILD), who has been working in the ILD unit of Wythenshawe Hospital since April 2018, for Manchester University NHS Foundation Trust. She is the lead of the Familial Interstitial Pneumonia clinic and the lead of ILD bronchoscopy list at Wythenshawe Hospital. Dr Rivera Ortega has spent three years as a clinical/research fellow and trained as a specialist in ILD with Dr Maria Molina-Molina at Bellvitge University Hospital, Barcelona-Spain. She is the former coordinator of the Emerging Spanish ILD group (GEEPID-SEPAR) and current member of the executive board of the Spanish ILD group (EPID-SEPAR). Dr Rivera Ortega participates as principal investigator and co-investigator of several clinical trials related to ILD. She has previous experience in the development of a rapid circuit for assessment of ILDs.

Prof. Fulvio Braido is Associate Professor in Respiratory Medicine at the University of Genoa, Italy, where he is the Head of the Respiratory Diseases & Allergy Department.
Fulvio Braido graduated cum laude in 1993 at the School of Medicine, University of Genoa and participated to the Respiratory Program Respiratory Diseases in 1993-1997 and in Allergy and Clinical Immunology 2002-2006 at the University of Genoa.
He is a researcher in Rhinitis, Asthma, COPD and Sleep Apnea (HI 38).
His main research interests are represented by development and assessmento f patient reported outcomes in respiratory and allergic diseases andthe physiopathological/immunological mechanisms.
Fulvio Braido has an excellent experience in clinical trials based on Good Clinical Practice. He is heavily engaged in teaching activities for the School of Medicine in Genoa, where he teaches Respiratory Diseases.
He is the president of Interasma - Global Asthma Association, former Executive Committee Member of the European Academy of Allergy and Clinical Immunology (EAACI).
He is the editor in chief of Journal of asthma.

Physician, specialist in Immunoallergy and Health Units Management. PhD in respiratory diseases.
Head of the Allergy Center of CUF-Descobertas Hospital (World Allergy Organization Center of Excellence).
President-elect of the World Allergy Organization (WAO).
President of the Portuguese Association of Asthmatic Patients.
Past-president of the Portuguese Society of Allergy and Clinical Immunology.

I work as Assistant Professor in the pulmonology department of Cochin Hospital in Paris, France, directed by Pr Roche.
I am a Cystic Fibrosis specialist in the “Reference Center for Rare Diseases – Cystic fibrosis and CFTR-RD” directed by Pr Burgel since September 2016. I am notably involved in the follow-up of cystic fibrosis patients and in the evaluation of the impact of CFTR modulators from ORKAMBI to KAFTRIO in patient’s evolution, through many academic studies.
I am in the process of creating a Center for Rare Diseases (OrphaLung) who will be dedicated to improve the etiological diagnosis and care of patients with non-Cystic Fibrosis diffuse bronchiectasis and enhance patient’s access to future clinical trials.